PALO ALTO, CA--(Marketwired - Mar 10, 2014) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of the IMPACT-PCP (Investigation ...

Patients With a Low Corus CAD Score Had 94% Reduced Odds of Referral to a Cardiologist; REGISTRY I Study Results Add to the Established Evidence Base Supporting the Clinical Utility of the Corus CAD ...

CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today results from a genomic substudy of the NHLBI-funded Prospective Multicenter Imaging Study for ...

REDWOOD CITY, CA--(Marketwired - Apr 12, 2017) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today the publication of results from the ...

CardioDx saw good news from Florida this week with the presentation of results from the COMPASS trial involving Corus CAD, a blood-based gene expression test for obstructive coronary artery disease.

Patients diagnosed with nonobstructive coronary artery disease (CAD) are at increased risk of myocardial infarction (MI) and mortality over the next year compared with those classified as having no ...

It's been a difficult year for CardioDx, but there may be light at the end of the tunnel: In a new study, researchers found that the company's genetic test for coronary artery disease could help ...

A study to examine recessively inherited genome-wide DNA sequences has for the first time discovered a potential link with Britain's biggest killer - Coronary Artery Disease (CAD). The research led by ...

(HealthDay News) — The presence of myocardial infarction (MI) without substantial coronary artery disease (CAD) is not familial, according to a study presented at the annual meeting of the American ...

Shockwave Medical Inc., a unit of Johnson & Johnson Medtech, reported positive 30-day results from the EMPOWER CAD trial, which used its intravascular lithotripsy system in women with complex, ...